| | 1093279-77-6 Basic information More.. |
| Product Name: | 2,4,6,8-Tetraoxa-5-phosphanonanedioic acid, 5-[[(1R)-2-[6-[[[[9-[(2R)-5-hydroxy-2,11-diMethyl-5-oxido-9-oxo-3,6,8,10-tetraoxa-5-phosphadodec-1-yl]-9H-purin-6-yl]aMino]Methyl]aMino]-9H-purin-9-yl]-1-Methylethoxy]Methyl]-, 1,9-bis(1-Methylethyl) ester, 5-ox | | Synonyms: | 2,4,6,8-Tetraoxa-5-phosphanonanedioic acid, 5-[[(1R)-2-[6-[[[[9-[(2R)-5-hydroxy-2,11-diMethyl-5-oxido-9-oxo-3,6,8,10-tetraoxa-5-phosphadodec-1-yl]-9H-purin-6-yl]aMino]Methyl]aMino]-9H-purin-9-yl]-1-Methylethoxy]Methyl]-, 1,9-bis(1-Methylethyl) ester, 5-ox;Mixed-POC DiMer;Tri-POC Tenofovir DiMer;Mixed dimer;Tenofov Mixed Dimer;((((((R)-1-(6-((((9-((R)-2-((bis(((isopropoxycarbonyl)oxy)methoxy)phosphoryl)methoxy)propyl)-9H-purin-6-yl)amino)methyl)amino)-9H-purin-9-yl)propan-2-yl)oxy)methyl)(hydroxy)phosphoryl)oxy)methyl isopropyl carbonate;Tenofovir Disoproxil Fumarate impurity M;Tenofovir disoproxil Impurity F | | CAS: | 1093279-77-6 | | MF: | C34H52N10O17P2 | | MW: | 934.78 | | EINECS: | | | Mol File: | 1093279-77-6.mol |  |
Use
Tri-POC Tenofovir Dimer is a dimer of Tenofovir Disoproxil (T018505), an acyclic phosphonate nucleotide analogue; reverse transcriptase inhibitor. Used as an anti-HIV agent. Antiviral. It is also used
in the preparation of phosphocitrate for the treatment of rheumatoid and osteoarthritis in the elderly.
|
|
1093279-77-6
Recommend Suppliers |
| Company Name: |
BeiJing Hwrk Chemicals Limted
Recommend
Complaint |
 |
| Tel: |
0757-86329057 |
| FAX: |
010-89508210 |
| Email: |
sales4.gd@hwrkchemical.com |
| Products Intro: |
Product Name:2,4,6,8-Tetraoxa-5-phosphanonanedioicacid,5-[[(1R)-2-[6-[[[[9-[(2R)-5-hydroxy-2,11-diMethyl-5-oxido-9-oxo-3,6,8,10-tetraoxa-5-phosphadodec-1-yl]-9H-purin-6-yl]aMino]Methyl]aMino]-9H-purin-9-yl]-1-Methylethoxy]Methyl]-,1,9-bis(1-Methylethyl)ester,5-ox
CAS:1093279-77-6
Purity:98.00% Package:25mg Remarks:HWG49183
More... |
| CB Index: |
55 |
| WebSite: |
www.hwrkchemical.com/ |
| Related Information: |
Sales Network
Catalog(14067)
User Evaluation(12)
|
|